This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Urolithin A
DrugBank Accession Number
DB15464
Background

Urolithin A is a metabolite of ellagic acid. It has been demonstrated to stimulate mitophagy and improve muscle health in old animals and in preclinical models of aging.1

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 228.2002
Monoisotopic: 228.042258744
Chemical Formula
C13H8O4
Synonyms
  • 3,8-Dihydroxyurolithin
  • 3,8-Hydroxydibenzo-alpha-pyrone

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as coumarins and derivatives. These are polycyclic aromatic compounds containing a 1-benzopyran moiety with a ketone group at the C2 carbon atom (1-benzopyran-2-one).
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Coumarins and derivatives
Sub Class
Not Available
Direct Parent
Coumarins and derivatives
Alternative Parents
Isocoumarins and derivatives / 2-benzopyrans / 1-benzopyrans / Pyranones and derivatives / 1-hydroxy-2-unsubstituted benzenoids / Heteroaromatic compounds / Lactones / Oxacyclic compounds / Organooxygen compounds / Organic oxides
show 1 more
Substituents
1-benzopyran / 1-hydroxy-2-unsubstituted benzenoid / 2-benzopyran / Aromatic heteropolycyclic compound / Benzenoid / Benzopyran / Coumarin / Heteroaromatic compound / Hydrocarbon derivative / Isocoumarin
show 8 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
ILJ8NEF6DT
CAS number
1143-70-0
InChI Key
RIUPLDUFZCXCHM-UHFFFAOYSA-N
InChI
InChI=1S/C13H8O4/c14-7-1-3-9-10-4-2-8(15)6-12(10)17-13(16)11(9)5-7/h1-6,14-15H
IUPAC Name
3,8-dihydroxy-6H-benzo[c]chromen-6-one
SMILES
OC1=CC2=C(C=C1)C1=C(C=C(O)C=C1)C(=O)O2

References

General References
  1. Pénélope A. Andreux, William Blanco-Bose, Dongryeol Ryu, Frédéric Burdet, Mark Ibberson, Patrick Aebischer, Johan Auwerx, Anurag Singh & Chris Rinsch: The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans Nature Metabolism. 2019 June 14;1:595–603. [Article]
Human Metabolome Database
HMDB0013695
ChemSpider
4589709
ChEMBL
CHEMBL1836264
ZINC
ZINC000013484727
Wikipedia
Urolithin_A

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.263 mg/mLALOGPS
logP2.16ALOGPS
logP2.32Chemaxon
logS-2.9ALOGPS
pKa (Strongest Acidic)7.21Chemaxon
pKa (Strongest Basic)-7.1Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area66.76 Å2Chemaxon
Rotatable Bond Count0Chemaxon
Refractivity60.9 m3·mol-1Chemaxon
Polarizability22.26 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-004i-0090000000-1cfecfbcd459b8f927aa
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-004i-0190000000-1fb96de3cadd65f74445
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-052s-0910000000-f66d25e749ba2d69c3ab
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-0190000000-637b053a07946e3af236
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-0390000000-e87f1d5246d5b9e763da
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-0910000000-11d70b77e5008c99715d

Drug created at June 18, 2019 22:52 / Updated at June 12, 2020 16:53